doxorubicin liposome

Doxorubicin liposome is a pegylated liposomal formulation of the anthracycline antineoplastic agent doxorubicin, developed and marketed by Jiangsu Simcere Pharmaceutical Co., Ltd. under the brand name Duoenda. The drug functions by intercalating into DNA and inhibiting the enzyme DNA topoisomerase II, which leads to the cessation of DNA replication and RNA synthesis, ultimately inducing apoptosis in rapidly dividing cancer cells. The liposomal encapsulation, specifically the pegylation, significantly alters the drug's pharmacokinetic profile by extending its half-life and allowing for passive targeting of tumor tissues through the enhanced permeability and retention (EPR) effect. This formulation is designed to minimize the systemic toxicities associated with conventional doxorubicin, such as cardiotoxicity and alopecia. In China, it is approved for the treatment of platinum-resistant recurrent ovarian cancer and is currently being investigated in Phase 3 trials (such as the SCORES study) in combination with the VEGF-targeting antibody suvemcitug for ovarian, fallopian tube, and primary peritoneal cancers.

Brand names

Duoenda

Other names

pegylated liposomal doxorubicinPLDdoxorubicin hydrochloride liposome injection